$0.98
1.89% yesterday
Nasdaq, Nov 25, 10:17 pm CET
ISIN
US88688T1007
Symbol
TLRY

Tilray, Inc. Series 2 Stock price

$0.98
-0.49 33.12% 1M
+0.54 122.24% 6M
-0.35 26.08% YTD
-0.44 30.76% 1Y
-2.87 74.46% 3Y
-6.49 86.84% 5Y
-21.41 95.61% 10Y
-21.41 95.61% 20Y
Nasdaq, Closing price Tue, Nov 25 2025
+0.02 1.89%
ISIN
US88688T1007
Symbol
TLRY
Industry

New AI Insights on Tilray, Inc. Series 2 Insights AI Insights on Tilray, Inc. Series 2

How does the company make money?
Who are the company’s main competitors?
What are the key opportunities and risks?
How is the company managed?

Key metrics

Basic
Market capitalization
$1.0b
Enterprise Value
$1.1b
Net debt
$33.6m
Cash
$264.8m
Shares outstanding
1.1b
Valuation (TTM | estimate)
P/E
negative | negative
P/S
1.2 | 1.2
EV/Sales
1.3 | 1.2
EV/FCF
negative
P/B
0.7
Financial Health
Equity Ratio
72.9%
Return on Equity
-144.7%
ROCE
-5.3%
ROIC
-5.3%
Debt/Equity
0.2
Financials (TTM | estimate)
Revenue
$830.8m | $881.4m
EBITDA
$-25.0m | $66.1m
EBIT
$-95.7m | $-78.6m
Net Income
$-2.1b | $-47.8m
Free Cash Flow
$-96.3m
Growth (TTM | estimate)
Revenue
2.3% | 7.3%
EBITDA
59.7% | 444.1%
EBIT
34.6% | 27.1%
Net Income
-910.2% | 97.8%
Free Cash Flow
-17.2%
Margin (TTM | estimate)
Gross
28.7%
EBITDA
-3.0% | 7.5%
EBIT
-11.5%
Net
-258.5% | -5.4%
Free Cash Flow
-11.6%
More
EPS
$-2.0
FCF per Share
$-0.1
Short interest
9.0%
Employees
3k
Rev per Employee
$310.0k
Show more

Is Tilray, Inc. Series 2 a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 7,053 stocks worldwide.

Tilray, Inc. Series 2 Stock Analysis

Unlock Scores for Free

Analyst Opinions

16 Analysts have issued a Tilray, Inc. Series 2 forecast:

7x Buy
44%
8x Hold
50%
1x Sell
6%

Analyst Opinions

16 Analysts have issued a Tilray, Inc. Series 2 forecast:

Buy
44%
Hold
50%
Sell
6%

Financial data from Tilray, Inc. Series 2

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Aug '25
+/-
%
831 831
2% 2%
100%
- Direct Costs 592 592
3% 3%
71%
238 238
0% 0%
29%
- Selling and Administrative Expenses 256 256
2% 2%
31%
- Research and Development Expense 0.22 0.22
67% 67%
0%
-25 -25
60% 60%
-3%
- Depreciation and Amortization 71 71
16% 16%
9%
EBIT (Operating Income) EBIT -96 -96
35% 35%
-12%
Net Profit -2,148 -2,148
910% 910%
-259%

In millions USD.

Don't miss a Thing! We will send you all news about Tilray, Inc. Series 2 directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Tilray, Inc. Series 2 Stock News

Neutral
GlobeNewsWire
one day ago
TORONTO, Nov. 24, 2025 (GLOBE NEWSWIRE) -- Tilray Brands, Inc., company (“Tilray”) (Nasdaq: TLRY; TSX: TLRY), a global lifestyle and consumer packaged goods company at the forefront of the cannabis, beverage, and wellness industries, today announced the introduction of Good Supply vape products in Québec as part of the launch of legal cannabis vaping products in Québec. Consumers in Québec will...
Positive
The Motley Fool
5 days ago
President Donald Trump appeared to endorse the health benefits of cannabidiol recently. Shares of Tilray, a leading cannabis producer, benefited -- hitting a new 52-week high.
Positive
MarijuanaStocks
7 days ago
The U.S. legal cannabis industry is showing strong momentum, and the time may be ripe to scan for promising Canadian-listed stocks. In fact, the U.S. market is projected to reach about US$45 billion in 2025, growing at roughly an 11-12 percent annual rate through the rest of the decade. Meanwhile, public support for reform sits near record levels, and recent headlines highlighted renewed federa...
More Tilray, Inc. Series 2 News

Company Profile

Tilray, Inc. engages in the research, cultivation, production, and distribution of medical cannabis and cannabinoids. The Company is focused on medical cannabis research, cultivation, processing and distribution of cannabis products worldwide. Its products include dried cannabis and cannabis extracts. It operates through the following segments: Cannabis and Hemp. The Cannabis segment sales consists of adult-use, medical and bulk sales of cannabis under regulated licenses and sold to retail, wholesale, pharmacy, government, and direct to patient. The Hemp segment sales consist of hemp seed, hemp foods, board spectrum hemp extract containing CBD which are sold in an unlicensed operation and sold to retail, wholesale and direct to consumers. The company was founded on January 24, 2018 and is headquartered in Nanaimo, Canada.

Head office United States
CEO Irwin Simon
Employees 2,650
Founded 2018
Website www.tilray.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today